Emergent BioSolutions (LTS:0IGA) Cyclically Adjusted Book per Share: $22.33 (As of Mar. 2026)


LTS:0IGA Emergent BioSolutions Inc LTS:0IGA
54 GF Score
Price $7.96
GF Value $4.65
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Emergent BioSolutions Cyclically Adjusted Book per Share?

Emergent BioSolutions LTS:0IGA -1.73% 54 Cyclically Adjusted Book per Share is $22.33 as of Mar. 2026. GuruFocus rates LTS:0IGA with a GF Score™ of 54/100 and a GF Value™ of $4.65 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Emergent BioSolutions's adjusted book value per share for the three months ended in Mar. 2026 was $10.098. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $22.33 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Emergent BioSolutions's average Cyclically Adjusted Book Growth Rate was -1.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 0.30% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 5.80% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 9.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Emergent BioSolutions was 13.50% per year. The lowest was 0.30% per year. And the median was 10.55% per year.

As of today (2026-07-12), Emergent BioSolutions's current stock price is $7.96. Emergent BioSolutions's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $22.33. Emergent BioSolutions's Cyclically Adjusted PB Ratio of today is 0.36.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Emergent BioSolutions was 8.34. The lowest was 0.07. And the median was 2.57.


Emergent BioSolutions  (LTS:0IGA) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Emergent BioSolutions's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=7.96/22.33
=0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Emergent BioSolutions was 8.34. The lowest was 0.07. And the median was 2.57.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Emergent BioSolutions Cyclically Adjusted Book per Share Related Terms


Emergent BioSolutions Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Emergent BioSolutions's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emergent BioSolutions Cyclically Adjusted Book per Share Chart

Emergent BioSolutions Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.48 21.97 39.25 22.60 22.66

Emergent BioSolutions Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.17 23.13 22.99 22.66 22.33

LTS:0IGA vs ELTP, NIKA, EOLS: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emergent BioSolutions Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's Cyclically Adjusted PB Ratio falls into.


LTS:0IGA
54GF Score
Emergent BioSolutions Inc LTS:0IGA
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Emergent BioSolutions Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Emergent BioSolutions's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=10.098/330.2130*330.2130
=10.098

Current CPI (Mar. 2026) = 330.2130.

Emergent BioSolutions Quarterly Data

Book Value per Share CPI Adj_Book
201606 16.638 241.018 22.795
201609 13.526 241.428 18.500
201612 14.694 241.432 20.097
201703 14.905 243.801 20.188
201706 15.097 244.955 20.352
201709 16.039 246.819 21.458
201712 18.466 246.524 24.735
201803 17.693 249.554 23.412
201806 18.761 251.989 24.585
201809 19.261 252.439 25.195
201812 19.744 251.233 25.951
201903 19.212 254.202 24.957
201906 19.165 256.143 24.707
201909 20.058 256.759 25.796
201912 21.054 256.974 27.055
202003 20.564 258.115 26.308
202006 22.662 257.797 29.028
202009 23.613 260.280 29.957
202012 27.250 260.474 34.546
202103 28.410 264.877 35.418
202106 28.747 271.696 34.938
202109 28.356 274.310 34.135
202112 31.413 278.802 37.206
202203 31.256 287.504 35.899
202206 30.325 296.311 33.795
202209 29.044 296.808 32.313
202212 27.699 296.797 30.818
202303 23.861 301.836 26.104
202306 18.461 305.109 19.980
202309 13.459 307.789 14.440
202312 12.439 306.746 13.391
202403 12.670 312.332 13.395
202406 7.302 314.175 7.675
202409 9.405 315.301 9.850
202412 8.886 315.605 9.297
202503 10.141 319.799 10.471
202506 9.985 322.561 10.222
202509 11.053 324.800 11.237
202512 10.031 324.054 10.222
202603 10.098 330.213 10.098

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $22.33 mean?
Emergent BioSolutions (LTS:0IGA) has a Cyclically Adjusted Book per Share of $22.33 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Emergent BioSolutions and its competitors.
Is Emergent BioSolutions' Cyclically Adjusted Book per Share too high?
Emergent BioSolutions' current Cyclically Adjusted Book per Share is $22.33. Overall, Emergent BioSolutions has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Emergent BioSolutions' Cyclically Adjusted Book per Share compare to ELTP and NIKA?
Emergent BioSolutions' Cyclically Adjusted Book per Share of $22.33 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Emergent BioSolutions and its competitors. Emergent BioSolutions's current Cyclically Adjusted Book per Share is $22.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emergent BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Emergent BioSolutions (LTS:0IGA) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.65, compared to a current price of $7.96 — trading 71.2% above its estimated fair value. The current Cyclically Adjusted Book per Share is $22.33. Emergent BioSolutions' overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Emergent BioSolutions (LTS:0IGA), the current Cyclically Adjusted Book per Share is $22.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Emergent BioSolutions (LTS:0IGA) Overvalued in 2026?

Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be overvalued. The current stock price of $7.96 is trading 71.2% above its estimated GF Value™ of $4.65. GuruFocus considers Emergent BioSolutions to be Significantly Overvalued.

Key valuation signals for LTS:0IGA:

  • Cyclically Adjusted Book per Share: $22.33
  • GF Value™: $4.65 vs. price of $7.96 (71.2% above fair value)
  • GF Score™: 54/100 with 5 warning signs

No single metric tells the full story. See the LTS:0IGA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Emergent BioSolutions Business Description

Other Exchanges EBS:USAER4:Germany
Address 300 Professional Drive, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
54GF Score

Get the complete analysis for LTS:0IGA

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.96
Price
$4.65
GF Value